德納利治療公司
US ˙ NasdaqGS ˙ US24823R1059

SecurityDNLI / Denali Therapeutics Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership229,457 shares
Latest Disclosed Value $ 3,210,103
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 8.27% increase in ownership of DNLI / Denali Therapeutics Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 229,457 shares of Denali Therapeutics Inc. (US:DNLI) valued at $3,210,103 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 211,929 shares of Denali Therapeutics Inc.. This represents a change in shares of 8.27% during the quarter. The current value of the position is $4,479,001 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Denali Therapeutics EC US24823R1059 229,457 17,528 8.27 3,210 11.42 0.0721
2025-05-28 2025-03-31 NP Denali Therapeutics EC US24823R1059 211,929 2,337 1.12 2,881 -32.55 0.0691
2025-02-25 2024-12-31 NP Denali Therapeutics EC US24823R1059 209,592 -34,362 -14.09 4,271 -39.90 0.0933
2024-11-26 2024-09-30 NP Denali Therapeutics EC US24823R1059 243,954 18,332 8.13 7,106 35.66 0.1344
2024-08-26 2024-06-30 NP Denali Therapeutics EC US24823R1059 225,622 17,259 8.28 5,239 22.53 0.1067
2024-05-28 2024-03-31 NP Denali Therapeutics EC US24823R1059 208,363 -6,759 -3.14 4,276 -7.39 0.0892
2024-02-26 2023-12-31 NP Denali Therapeutics EC US24823R1059 215,122 14,782 7.38 4,617 11.69 0.0985
2023-11-28 2023-09-30 NP Denali Therapeutics EC US24823R1059 200,340 -3,674 -1.80 4,133 -31.35 0.1078
2023-08-25 2023-06-30 NP Denali Therapeutics EC US24823R1059 204,014 29,286 16.76 6,020 49.57 0.1428
2023-05-26 2023-03-31 NP Denali Therapeutics EC US24823R1059 174,728 4,659 2.74 4,026 -14.89 0.1072
2023-02-24 2022-12-31 NP Denali Therapeutics EC US24823R1059 170,069 13,839 8.86 4,730 -1.36 0.1301
2022-11-25 2022-09-30 NP Denali Therapeutics EC US24823R1059 156,230 4,015 2.64 4,795 7.03 0.1374
2022-08-25 2022-06-30 NP Denali Therapeutics EC US24823R1059 152,215 10,727 7.58 4,480 -1.58 0.1237
2022-05-26 2022-03-31 NP Denali Therapeutics EC US24823R1059 141,488 2,078 1.49 4,552 -26.80 0.1060
2022-02-25 2021-12-31 NP Denali Therapeutics EC US24823R1059 139,410 2,068 1.51 6,218 -10.26 0.1349
2021-11-24 2021-09-30 NP Denali Therapeutics EC US24823R1059 137,342 -3,005 -2.14 6,929 -37.06 0.1526
2021-08-26 2021-06-30 NP Denali Therapeutics EC US24823R1059 140,347 44,951 47.12 11,009 102.09 0.2362
2021-05-27 2021-03-31 NP Denali Therapeutics EC US24823R1059 95,396 -2,642 -2.69 5,447 -33.66 0.1235
2021-02-25 2020-12-31 NP Denali Therapeutics EC US24823R1059 98,038 -4,978 -4.83 8,212 122.46 0.2104
2020-11-25 2020-09-30 NP Denali Therapeutics EC US24823R1059 103,016 -3,168 -2.98 3,691 43.79 0.1184
2020-08-27 2020-06-30 NP Denali Therapeutics EC US24823R1059 106,184 21,326 25.13 2,568 72.86 0.0839
2020-06-01 2020-03-31 NP Denali Therapeutics EC US24823R1059 84,858 10,829 14.63 1,486 15.21 0.0607
2020-02-27 2019-12-31 NP Denali Therapeutics EC 24823R105 74,029 890 1.22 1,290 15.09 0.0388
2019-11-27 2019-09-30 NP Denali Therapeutics EC US24823R1059 73,139 73,139 1,120 0.0370
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.